Home » Faced With Illumina's Solexa Bid, Affy Says New Sequencing Shops Still too Immature to Buy

Faced With Illumina's Solexa Bid, Affy Says New Sequencing Shops Still too Immature to Buy

Nov 22, 2006
NEW YORK (GenomeWeb News) — A few days after Illumina last week said it plans to buy next-generation sequencing company Solexa, rival Affymetrix said it wasn’t about to follow suit.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Scan

Best Options

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

A Butterfly's Wings

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

This Week in PNAS

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Pathogen Tracking

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.

What's Popular?

In Microarrays & Multiplexing

  1. Cornell Seeks to Rescind Settlement of Patent Dispute Against Illumina

  2. Genentech Adapts Microfluidics Sequencing Method for Liquid Biopsy Applications

    Premium

  3. Researchers Identify SNP Set, Develop QR Code to Distinguish Genome Samples

  4. RNA-Editing Protein ADAR Promotes Progression of Lung Cancer, New Study Finds

  5. Papua New Guinea Population Patterns Point to Past Isolation, Diversification

Sponsorships

Privacy Policy.  Copyright © 2017 GenomeWeb LLC.  All Rights Reserved.